Madrigal Pharmaceuticals, Inc. (MDGL) EPS Estimated At $-0.68

March 15, 2018 - By Kurt Siggers

 Madrigal Pharmaceuticals, Inc. (MDGL) EPS Estimated At $ 0.68

Analysts expect Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to report $-0.68 EPS on April, 2.They anticipate $0.01 EPS change or 1.49 % from last quarter’s $-0.67 EPS. After having $-0.68 EPS previously, Madrigal Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 6.14% or $7.83 during the last trading session, reaching $119.52. About 592,703 shares traded or 163.82% up from the average. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $1.67 billion. The company's lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

More news for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) were recently published by:, which released: “Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial …” on March 13, 2018.‘s article titled: “Madrigal Pharmaceuticals: Well-Funded To Fill An Unmet Need” and published on March 13, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: